scholarly journals Interpreting Overall Survival (OS) Results When Progression Free Survival (PFS) Benefits Exists in Today's Oncology Landscape - Metastatic Renal Cell Carcinoma (Mrcc) Case Study

2012 ◽  
Vol 23 ◽  
pp. ix453-ix454
Author(s):  
S. Negrier ◽  
Y. Tang ◽  
C. Chen ◽  
P. Bycott
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Free Survival

scholarly journals Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC)

2012 ◽  
Vol 23 ◽  
pp. ix270-ix271 ◽  
Author(s):  
R. Iacovelli ◽  
M. Santoni ◽  
G. Di Lorenzo ◽  
L. Cerbone ◽  
M. Aglietta ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Free Survival

O5 Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)

2012 ◽  
Vol 11 (5) ◽  
pp. 185-186
Author(s):  
R. Iacovelli ◽  
M. Milella ◽  
M. Santoni ◽  
G. Di Lorenzo ◽  
L. Cerbone ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Free Survival

scholarly journals Effect of Concomitant pH‐Elevating Medications with Pazopanib on Progression‐Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma

2018 ◽  
Vol 23 (6) ◽  
pp. 686-692 ◽  
Author(s):  
Renee K. McAlister ◽  
Jonathan Aston ◽  
Megan Pollack ◽  
Liping Du ◽  
Tatsuki Koyama ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Free Survival

Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma

2019 ◽  
Vol 26 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Winnie Cheng ◽  
Victoria Kletas ◽  
Christian Kollmannsberger ◽  
Mário de Lemos
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Survival Outcomes ◽  
Free Survival ◽  
Dosing Regimens ◽  
Continuous Dosing

Background Standard dosing regimen of sunitinib for metastatic renal cell carcinoma consists of four weeks treatment followed by two weeks rest (intermittent dosing). Alternative regimens have been suggested, including continuous daily dosing (continuous dosing) and non-conventional dosing (non-conventional dosing: e.g. two weeks on/one week off, non-conventional dosing), to provide more individualized therapy with less toxicities. It is unclear whether non-standard sunitinib dosing affects survival outcomes. Patients Metastatic renal cell carcinoma patients treated with sunitinib between 1 July 2007 and 1 July 2011 at our institution. Methods Medical records and dispensing data were reviewed retrospectively to categorize sunitinib dosing as intermittent dosing, continuous dosing, or non-conventional dosing. Primary outcome was to compare overall survival associated with varying regimens, with secondary outcomes of progression-free survival and incidence of treatment discontinuation due to adverse effects. Results A total of 180 patients were identified. Most patients received intermittent dosing ( n = 120, 67%), followed by continuous dosing ( n = 32, 18%) and non-conventional dosing ( n = 28, 16%). Compared to intermittent dosing, continuous dosing was associated with similar overall survival (median 9 vs. 13 months, HR 0.67, 95% CI: 0.43–1.06, p = 0.088) while non-conventional dosing was associated with significantly longer overall survival (median 9 vs. 23 months, HR 0.55, 95% CI: 0.34–0.90, p = 0.016). Progression-free survival was significantly better for continuous dosing (median 4 vs. 9 months, HR 0.61, 95% CI: 0.40–0.94, p = 0.025) and non-conventional dosing (median 4 vs. 10 months, HR 0.61, 95% CI: 0.39–0.95, p = 0.03) when compared to intermittent dosing. Similar to prior sunitinib trials, a significant proportion of patients (20%) discontinued sunitinib therapy due to adverse effects. Conclusions Based on retrospective, real-world data, alternative sunitinib dosing regimens appear to be viable options for patients with metastatic renal cell carcinoma.

1301 POSTER Assessment of Progression-free Survival as a Surrogate Endpoint for Overall Survival in Patients With Metastatic Renal Cell Carcinoma

2011 ◽  
Vol 47 ◽  
pp. S163
Author(s):  
S. Neqrier ◽  
A.G. Bushmakin ◽  
J.C. Cappelleri ◽  
C. Charbonneau ◽  
R. Sandin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Surrogate Endpoint ◽  
Free Survival

scholarly journals Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy

Cancer ◽  
2010 ◽  
Vol 117 (12) ◽  
pp. 2637-2642 ◽  
Author(s):  
Daniel Y. C. Heng ◽  
Wanling Xie ◽  
Georg A. Bjarnason ◽  
Ulka Vaishampayan ◽  
Min-Han Tan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Free Survival
Sign in / Sign up

Export Citation Format

Share Document